KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E Adjustments
Ratios

TherapeuticsMD (TXMD) Amortization - Deferred Charges (2020 - 2022)

Historic Amortization - Deferred Charges for TherapeuticsMD (TXMD) over the last 3 years, with Q3 2022 value amounting to $2.6 million.

  • TherapeuticsMD's Amortization - Deferred Charges rose 7481.38% to $2.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $21.1 million, marking a year-over-year increase of 31791.87%. This contributed to the annual value of $5.7 million for FY2021, which is 12468.4% up from last year.
  • Latest data reveals that TherapeuticsMD reported Amortization - Deferred Charges of $2.6 million as of Q3 2022, which was up 7481.38% from $7.9 million recorded in Q2 2022.
  • TherapeuticsMD's 5-year Amortization - Deferred Charges high stood at $9.0 million for Q1 2022, and its period low was $372000.0 during Q2 2020.
  • In the last 3 years, TherapeuticsMD's Amortization - Deferred Charges had a median value of $1.4 million in 2021 and averaged $2.7 million.
  • In the last 5 years, TherapeuticsMD's Amortization - Deferred Charges surged by 5498.43% in 2021 and then skyrocketed by 61132.08% in 2022.
  • Quarter analysis of 3 years shows TherapeuticsMD's Amortization - Deferred Charges stood at $887000.0 in 2020, then skyrocketed by 72.6% to $1.5 million in 2021, then soared by 68.65% to $2.6 million in 2022.
  • Its last three reported values are $2.6 million in Q3 2022, $7.9 million for Q2 2022, and $9.0 million during Q1 2022.